Cullinan Therapeutics (CGEM) Liabilities and Shareholders Equity (2020 - 2026)

Cullinan Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $403.0 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 30.48% year-over-year to $403.0 million; the TTM figure through Mar 2026 stood at $1.9 billion (down 26.82% YoY), while the FY2025 annual figure was $448.4 million, down 27.89% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $403.0 million, down from $448.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $681.2 million in Q2 2024, with the low at $403.0 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $520.3 million (2025), against an average of $537.7 million.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity soared 43.69% in 2022, then sank 30.48% in 2026.
• Cullinan Therapeutics' Liabilities and Shareholders Equity stood at $561.1 million in 2022, then retreated by 13.71% to $484.2 million in 2023, then climbed by 28.43% to $621.8 million in 2024, then slipped by 27.89% to $448.4 million in 2025, then retreated by 10.12% to $403.0 million in 2026.
• Business Quant data shows CGEM's Liabilities and Shareholders Equity at $403.0 million in Q1 2026, $448.4 million in Q4 2025, and $484.1 million in Q3 2025.